CHENGDU, China, Feb. 5, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2012 ending December 31, 2011 to be held at 8:30 a.m. ET on Tuesday, February 14, 2012. Interested parties may access the call by dialing +1-877-941-1427 (U.S.), 1-480-629-9664 (International) The conference ID is 4512254. It is advisable to dial in approximately 5 minutes prior to the start of the call. A replay will be available by calling +1-877-870-5176 (U.S.), 1-858-384-5517 (International), from 2/14/2012 at 11:30 am ET till 2/28/2012 at 11:59 pm ET, Replay Pin Number: 4512254 This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00009369 About TPI Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees. For more information about TPI, please visit: http://www.tianyinpharma.com. Safe Harbor Statement The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.